<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Transcode Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/transcode-therapeutics-inc</link>
<description>Latest news and press releases for Transcode Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 12:02:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/transcode-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b95078dffbe2df11565d.webp</url>
<title>Transcode Therapeutics Inc</title>
<link>https://6ix.com/company/transcode-therapeutics-inc</link>
</image>
<item>
<title>TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University</title>
<link>https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-appoints-dr-anna-moore-as-chair-of-scientific-advisory-board-announces-sponsored-research-agreement-with-michigan-state-university</link>
<guid isPermaLink="true">https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-appoints-dr-anna-moore-as-chair-of-scientific-advisory-board-announces-sponsored-research-agreement-with-michigan-state-university</guid>
<pubDate>Mon, 27 Apr 2026 12:02:00 GMT</pubDate>
<description>TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering RNA and immuno-oncology therapeutics for the treatment of high risk and advanced cancers, today announced the appointment of Anna Moore, PhD, as Chair of its Scientific Advisory Board and the signing of a sponsored research agreement (SRA) with Michigan State University (MSU).</description>
</item>
<item>
<title>TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028</title>
<link>https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-enters-into-agreements-for-up-to-dollar20-million-flexible-financing-extending-companys-runway-into-late-2027early-2028</link>
<guid isPermaLink="true">https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-enters-into-agreements-for-up-to-dollar20-million-flexible-financing-extending-companys-runway-into-late-2027early-2028</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>BOSTON, April 7, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ, the "Company"), a clinical stage company pioneering immuno-oncology and RNA</description>
</item>
<item>
<title>TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients</title>
<link>https://6ix.com/company/transcode-therapeutics-inc/news/transcode-secures-exclusive-worldwide-fully-paid-up-royalty-free-license-to-develop-and-commercialize-a-next-generation-oncolytic-immunotherapy-platform-in-an-all-stock-transaction-underscoring-the-companys-dedication-to-improving-the-lives-of-cancer-patients</link>
<guid isPermaLink="true">https://6ix.com/company/transcode-therapeutics-inc/news/transcode-secures-exclusive-worldwide-fully-paid-up-royalty-free-license-to-develop-and-commercialize-a-next-generation-oncolytic-immunotherapy-platform-in-an-all-stock-transaction-underscoring-the-companys-dedication-to-improving-the-lives-of-cancer-patients</guid>
<pubDate>Tue, 03 Mar 2026 13:01:00 GMT</pubDate>
<description>TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has entered into an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics, Inc. ("Unleash"). TransCode obtained the rights to develop three Unleash drug candidates, UIO-524, UIO-525 and UIO-526, which includes a license of all in-licensed rights held by Unleash to the Unleas</description>
</item>
<item>
<title>TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Canc...</title>
<link>https://6ix.com/company/transcode-therapeutics-inc/news/transcode-secures-exclusive-worldwide-fully-paid-up-royalty-free-license-to-develop-and-commercialize-a-next-generation-oncolytic-immunotherapy-platform-in-an-all-stock-transaction-underscoring-the-companys-dedication-to-improving-the-lives-of-canc</link>
<guid isPermaLink="true">https://6ix.com/company/transcode-therapeutics-inc/news/transcode-secures-exclusive-worldwide-fully-paid-up-royalty-free-license-to-develop-and-commercialize-a-next-generation-oncolytic-immunotherapy-platform-in-an-all-stock-transaction-underscoring-the-companys-dedication-to-improving-the-lives-of-canc</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in</description>
</item>
<item>
<title>TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development</title>
<link>https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-announces-publication-of-preclinical-testing-of-rig-i-immunotherapeutic-candidate-supporting-further-development</link>
<guid isPermaLink="true">https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-announces-publication-of-preclinical-testing-of-rig-i-immunotherapeutic-candidate-supporting-further-development</guid>
<pubDate>Mon, 23 Feb 2026 13:01:00 GMT</pubDate>
<description>TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers, today announced the publication of a manuscript titled Template-Directed RIG-I Agonist Assembly for Image-guided Targeted Cancer Immunotherapy in the journal Molecular Imaging and Biology. The paper, published February 19, 2026, reports on a novel tumor-selective immunotherapy approach that activates innate immune signaling spe</description>
</item>
<item>
<title>TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138</title>
<link>https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-quantum-leap-announce-130400300</link>
<guid isPermaLink="true">https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-quantum-leap-announce-130400300</guid>
<pubDate>Thu, 05 Feb 2026 13:04:00 GMT</pubDate>
<description>TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers, in collaboration with Quantum Leap Healthcare Collaborative (Quantum Leap), today announced the submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application amendment for a planned Phase 2a clinical trial with TransCode's lead therapeutic candidate, TTX-MC138. The study</description>
</item>
<item>
<title>TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma</title>
<link>https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-announces-publication-preclinical-130100226</link>
<guid isPermaLink="true">https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-announces-publication-preclinical-130100226</guid>
<pubDate>Tue, 06 Jan 2026 13:01:00 GMT</pubDate>
<description>TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancer, today announced the publication of preclinical research supporting the application of its lead candidate, TTX-MC138, for the treatment of glioblastoma multiforme (GBM). The article was published in the peer-reviewed Journal of Functional Biomaterials (Volume 17, Issue 1). The study, entitled "Nanotherapy Targeting miR-10b Improv</description>
</item>
<item>
<title>TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors</title>
<link>https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-expands-leadership-appointment-130100693</link>
<guid isPermaLink="true">https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-expands-leadership-appointment-130100693</guid>
<pubDate>Mon, 22 Dec 2025 13:01:00 GMT</pubDate>
<description>TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee. Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development</description>
</item>
<item>
<title>TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial</title>
<link>https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-quantum-leap-healthcare-130500541</link>
<guid isPermaLink="true">https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-quantum-leap-healthcare-130500541</guid>
<pubDate>Thu, 11 Dec 2025 13:05:00 GMT</pubDate>
<description>TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate TransCode's lead therapeutic candidate TTX-MC138 as part of the Quantum Leap PRE-I-SPY clinical trial platform.</description>
</item>
<item>
<title>TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer</title>
<link>https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-expands-executive-team-130100983</link>
<guid isPermaLink="true">https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-expands-executive-team-130100983</guid>
<pubDate>Mon, 17 Nov 2025 13:01:00 GMT</pubDate>
<description>TransCode Therapeutics, Inc. (NASDAQ: RNAZ), an immuno-oncology and targeted cancer therapy company with a focus on treating advanced malignancy, announced today the appointment of Dr. Michel Janicot, Ph.D., as consultant Senior Development Officer. Dr. Janicot brings more than 35 years of experience in pharmaceutical research, preclinical, and early clinical drug development across oncology and other therapeutic areas. He will serve initially on a part-time basis.</description>
</item>
<item>
<title>TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO</title>
<link>https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-presents-preliminary-data-120600247</link>
<guid isPermaLink="true">https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-presents-preliminary-data-120600247</guid>
<pubDate>Tue, 14 Oct 2025 12:06:00 GMT</pubDate>
<description>TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announces completion of Phase 1a clinical trial with TTX-MC138, an investigational inhibitor of microRNA-10b, or miR-10b. By meeting its primary safety endpoint and defining a recommended Phase 2 dose, TTX-MC138 is moving forward into the next stage of clinical evaluation to assess its efficacy across selected metastatic diseases and for multiple indications.</description>
</item>
<item>
<title>TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company</title>
<link>https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-rnaz-announces-acquisition-120100448</link>
<guid isPermaLink="true">https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-rnaz-announces-acquisition-120100448</guid>
<pubDate>Wed, 08 Oct 2025 12:01:00 GMT</pubDate>
<description>TransCode Therapeutics, Inc. (NASDAQ: RNAZ) ("TransCode or the "Company") announced today that it entered into a definitive agreement to acquire Polynoma LLC, a privately-held biotechnology immuno-oncology company. Polynoma is developing a late-stage candidate, seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of stage IIB and IIC melanoma.</description>
</item>
<item>
<title>TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board</title>
<link>https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-appoints-dr-phillip-120000147</link>
<guid isPermaLink="true">https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-appoints-dr-phillip-120000147</guid>
<pubDate>Wed, 28 May 2025 12:00:00 GMT</pubDate>
<description>TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a clinical-stage oncology company developing RNA-targeted therapeutics for the treatment of cancer, today announced the appointment of Phillip D. Zamore, Ph.D., to its Scientific Advisory Board. Dr. Zamore is a prominent biotechnology innovator known for his pioneering work in RNA interference (RNAi). Together with world-renowned scientists, including Nobel Laureate, Dr Phillip Sharp, he co-founded Alnylam Pharmaceuticals in 2002, which developed the</description>
</item>
<item>
<title>TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported</title>
<link>https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-successfully-completes-initial-120500951</link>
<guid isPermaLink="true">https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-successfully-completes-initial-120500951</guid>
<pubDate>Thu, 08 May 2025 12:05:00 GMT</pubDate>
<description>TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the third patient in Cohort 4 of its Phase 1a clinical trial has received their initial dose of TTX-MC138. All cohorts have enrolled at least three patients who have been dosed with TTX-MC138 at least once. The Safety Review Committee monitoring the clinical trial unanimously approved opening the fourth cohort based on its review of avai</description>
</item>
<item>
<title>TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split</title>
<link>https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-announces-effective-date-210000844</link>
<guid isPermaLink="true">https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-announces-effective-date-210000844</guid>
<pubDate>Mon, 05 May 2025 21:00:00 GMT</pubDate>
<description>TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved an effective time at 12:01 a.m. Eastern Standard Time May 15, 2025, for its 1-for-28 reverse stock split. TransCode's common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market on May 15, 2025, under the current trading symbol, "RNAZ</description>
</item>
<item>
<title>TransCode Therapeutics Announces 1-for-28 Reverse Stock Split</title>
<link>https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-announces-1-28-201000413</link>
<guid isPermaLink="true">https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-announces-1-28-201000413</guid>
<pubDate>Fri, 02 May 2025 20:10:00 GMT</pubDate>
<description>TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved a 1-for-28 reverse stock split. The reverse stock split was approved by TransCode's stockholders on May 2, 2025, and is intended to increase the per share trading price of the Company's common stock to enable the Company to satisfy the minimum bid price requirement for c</description>
</item>
<item>
<title>IBN Coverage: TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138</title>
<link>https://6ix.com/company/transcode-therapeutics-inc/news/ibn-coverage-transcode-therapeutics-nasdaq-rnaz-advances-phase-1a-trial-of-rna-cancer-therapy-ttx-mc138</link>
<guid isPermaLink="true">https://6ix.com/company/transcode-therapeutics-inc/news/ibn-coverage-transcode-therapeutics-nasdaq-rnaz-advances-phase-1a-trial-of-rna-cancer-therapy-ttx-mc138</guid>
<pubDate>Thu, 01 May 2025 18:30:00 GMT</pubDate>
<description>This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - May 1, 2025 (NEWMEDIAWIRE) - TransCode Therapeutics (NASDAQ: RNAZ) reported continued ...</description>
</item>
<item>
<title>TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer</title>
<link>https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-reports-further-progress-130100781</link>
<guid isPermaLink="true">https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-reports-further-progress-130100781</guid>
<pubDate>Thu, 01 May 2025 13:01:00 GMT</pubDate>
<description>TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced further progress in its Phase 1a clinical trial of TTX-MC138 in patients with metastatic cancer. TTX-MC138 is a first-in-class therapeutic candidate designed to inhibit microRNA-10b, or miR-10b, a microRNA widely believed to be critical to the emergence and progression of many metastatic cancers. To date, 13 patients have received at least on</description>
</item>
<item>
<title>TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting</title>
<link>https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-inc-announces-adjournment-203000323</link>
<guid isPermaLink="true">https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-inc-announces-adjournment-203000323</guid>
<pubDate>Mon, 21 Apr 2025 20:30:00 GMT</pubDate>
<description>TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced its Special Meeting scheduled for and convened on April 21, 2025, (the "Special Meeting") has been adjourned until May 2, 2025, at 9:30 a.m. Eastern time (the "Adjourned Special Meeting") for the purpose of soliciting additional votes with respect to the proposals outlined below and described in the Company's d</description>
</item>
<item>
<title>TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138</title>
<link>https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-announces-initial-dosing-203700928</link>
<guid isPermaLink="true">https://6ix.com/company/transcode-therapeutics-inc/news/transcode-therapeutics-announces-initial-dosing-203700928</guid>
<pubDate>Thu, 27 Mar 2025 20:37:00 GMT</pubDate>
<description>TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the first patient in Cohort 4 of its Phase I clinical trial has received their initial dose. TransCode also reported that two additional patients in Cohort 4 are scheduled to receive TTX-MC138. The therapeutic candidate being evaluated, TTX-MC138, is TransCode's lead candidate designed to inhibit microRNA-10b, a microRNA critical to the</description>
</item>
</channel>
</rss>